After Yesterday's Decline of 1.55%, InterMune Offers Investors Better Value
Comtex SmarTrend(R) - Tue Apr 15, 5:23PM CDT
InterMune (NASDAQ:ITMN) traded in a range yesterday that spanned from a low of $24.27 to a high of $28.18. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $26.26 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Shares of ITMN Up 98.8% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Apr 15, 9:07AM CDT
SmarTrend identified an Uptrend for InterMune (NASDAQ:ITMN) on February 12th, 2014 at $13.97. In approximately 2 months, InterMune has returned 98.78% as of today's recent price of $27.77.
Biotech Tweet of the Week: Love Being Private
Brian Orelli, The Motley Fool - Motley Fool - Mon Apr 14, 4:57PM CDT
This week's tweet of the week comes from Luke Timmerman, with a quote from Moderna Therapeutics' President and CEO Stephane Bancel, who says he loves being a private company because he has more control over what information gets released. Public...
Insider Trading Alert - ITMN, DXCM And MU Traded By Insiders
at The Street - Fri Apr 04, 10:30AM CDT
Stocks with insider trader activity include ITMN, DXCM and MU
Tradable Biotech Stocks Events For the Second Quarter
at The Street - Thu Apr 03, 8:00AM CDT
The biotech sector's March "fluctuation" might be a temporary speed bump or the beginning of a longer downturn. Either way, investors can still count on the biotech catalyst trade for chills and thrills.
Why InterMune Inc. Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:36PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of InterMune , a biopharmaceutical company...
Nasdaq stocks posting largest percentage increases
AP - Fri Mar 21, 12:24PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Use Options For A Chance To Buy ITMN At A 53% Discount
at The Street - Fri Mar 21, 10:57AM CDT
Looking back to 8 days ago, InterMune Inc. priced a 7,500,000 share secondary stock offering at $32.75 per share.
Horizon Pharma To Buy Vidara, Join Exodus To Ireland
at Investor's Business Daily - Wed Mar 19, 9:45AM CDT
Horizon Pharma (HZNP) followed many of its fellow drugmakers to Ireland Wednesday as it agreed to buy Dublin-based Vidara Therapeutics in a deal worth $660 million. Horizon shares jumped 17% in the stock market today, hitting an all-time high....
Today’s Top Biotech Stories: Horizon Pharma, Prothena, and Portola Pharmaceuticals
Leo Sun, The Motley Fool - Motley Fool - Wed Mar 19, 8:35AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at three stocks -- Horizon Pharma , ...
Better Buyout Candidate: Chelsea Therapeutics International Ltd. vs. InterMune Inc.
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
As more key drugs come off of patent protection, one of the central themes in biotech this year is the buyout. Companies like AstraZeneca plc and Eli Lilly , that have been deeply stricken by the so-called patent cliff, will undoubtedly be on the...
Approved Equities, Voluntary Recall, and New Product Launches - Analyst Notes on Baxter, Agilent, InterMune, Intuitive Surgical, and Mindray
PR Newswire - Fri Mar 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), Agilent Technologies Inc. (NYSE: A), InterMune Inc. (NASDAQ: ITMN), Intuitive Surgical, Inc. (NASDAQ: ISRG), and Mindray Medical International Ltd (NYSE: MR). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
InterMune Announces Pricing of Public Offering of 7,500,000 Shares of Common Stock
PR Newswire - Thu Mar 13, 6:20PM CDT
InterMune, Inc. (Nasdaq: ITMN) today announced that it has agreed to sell 7,500,000 shares of its common stock at a price to the public of $32.75 per share in an underwritten public offering. InterMune has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering. InterMune estimates net proceeds from the offering to be approximately $233.0 million (assuming no exercise of the underwriters' option to purchase additional shares of common stock), after deducting underwriting discounts and estimated offering expenses. InterMune intends to use the net proceeds from the offering to fund the commercialization activities in anticipation of the potential commercial launch of Esbriet® (pirfenidone) in the United States and ongoing commercialization in Europe, to fund research and development programs with Esbriet and other compounds intended to address idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases, and for general corporate purposes. InterMune expects to close this transaction on or about March 19, 2014, subject to satisfaction of customary closing conditions.
InterMune Announces Proposed Public Offering of Common Stock
PR Newswire - Wed Mar 12, 3:02PM CDT
InterMune, Inc. (NASDAQ: ITMN) today announced that it plans to offer, subject to market and other conditions, 7,500,000 shares of its common stock in an underwritten public offering. The company expects to grant the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock in connection with the offering. All of the shares in the offering will be sold by InterMune. The shares will be issued pursuant to a prospectus supplement filed as part of a shelf registration statement previously filed with the Securities and Exchange Commission (SEC) on Form S-3.
Biotech Stock Roundup: Amgen, Regeneron Slide on PCSK9 Inhibitor Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 12, 9:50AM CDT
Last week's highlights include safety concerns regarding a new class of drugs and takeover rumors.
Insider Trading Alert - ITMN, M And ILMN Traded By Insiders
at The Street - Wed Mar 12, 9:45AM CDT
Stocks with insider trader activity include ITMN, M and ILMN
, Terra Tech OTCQB TRTC Share price Grows Green up 16%
M2 - Wed Mar 12, 9:23AM CDT
March 12, 2014 Vancouver (321gostocks) -- Biotech news and Marijuana's continued rise in growing demand results in companies taking steps to advantage of strategic alliances: OSL Holdings, Inc. (OTC: OSLH), Terra Tech Corp. (OTC: TRTC), Growlife, Inc. (OTCBB: PHOT), Medical Marijuana, Inc. (OTC: MJNA) and InterMune, Inc. (NASDAQ: ITMN).
Why InterMune, Inc. Shares Rallied This Morning
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 11, 9:26AM CDT
While Fools should generally take the opinion of Wall Street with a grain of salt, it's not a bad idea to take a look at particularly stock-shaking analyst upgrades and downgrades -- just in case their reasoning behind the call makes sense. ...
InterMune Rises on Takeover Rumor - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 4:00PM CDT
Shares of InterMune were up around 10.8% on Mar 7 to end the day's trading at $33.87
Top Gainers under the Lens: Advanced Micro Devices, Big Lots, InterMune, and Palo Alto Networks
PR Newswire - Mon Mar 10, 12:38PM CDT
The US markets saw a mixed sentiment on Friday, March 07, 2014, with the NASDAQ Composite closing at 4,336.22, down 0.37%, the Dow Jones Industrial Average ending the session at 16,452.72, up 0.19% and the S&P 500 edging 0.05% higher to finish the trading session at 1,878.04. During the session, gains in the Financials, Energy and Industrials sectors positively impacted the broader market, while some retraction came in from Health Care, Materials and Information Technology sectors. A number of stocks saw large movements, including Advanced Micro Devices Inc. (NYSE: AMD), Big Lots Inc. (NYSE: BIG), InterMune Inc. (NASDAQ: ITMN), and Palo Alto Networks Inc. (NYSE: PANW), which were amongst the top gainers for the session. Free research on these four companies can be accessed at: